<DOC>
	<DOCNO>NCT01728324</DOCNO>
	<brief_summary>The aim study confirm efficacy safety treatment 600 mg BID BI 207127 combination 120 mg QD FDV RBV 16 24 week target chronically infected HCV GT1b treatment na√Øve patient , include patient compensated cirrhosis .</brief_summary>
	<brief_title>Phase 3 Study BI 207127 Combination With Faldaprevir Ribavirin Treatment Patients With Hepatitis C Infection , Including Patients Who Are Not Eligible Receive Peginterferon : HCVerso2</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Inclusion criterion : 1 . Chronic hepatitis C infection , diagnose positive antiHCV antibody detect HCV RNA screen 2 . HCV infection subGT1b confirm genotypic test screening . 3 . HCV viral load =1,000 IU/mL randomisation . 4 . Patients never previously treat HCV treatment regimen . Exclusion criterion : 1 . HCV infection mixed GT ( 1/2 , 1/3 , 1/4 ) diagnose genotypic test screening . 2 . HCV infection subGT1a , mixed GT1a/1b , undefined GT1 . 3 . Liver disease due cause chronic HCV infection . 4 . HIV infection . 5 . Hepatitis B virus infection base presence HBsAg . 6 . Confirmed suspect active malignancy history malignancy within last 5 year prior screen . 7 . History illicit drug abuse cannabis chronic alcohol abuse within 12 month prior randomisation . 8 . Subject willing comply precautionary measure prevent photosensitivity ( avoid excessive sun exposure use sun block daily basis ) . 9 . Decompensated liver disease , history decompensated liver disease . 10 . Clinical evidence unstable cardiovascular disease may decompensate due anemia . 11 . Red blood cell disorder . 12 . Body weight &lt; 40 kg &gt; 125 kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>